NYSE:ZTS

Post Image
Zoetis Wins USDA License for 3-in-1 Poultry Vaccine

Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Poulvac Procerta HVT-ND-ILT, a new vector vaccine designed to protect chickens against Marek’s disease, Newcastle disease and infectious laryngotracheitis.

The 3-in-1 vaccine is labeled for use in healthy one-day-old chickens or 18- to 19-day-old embryonated eggs and is intended to give veterinarians and poultry producers greater flexibility when designing flock-health programs.

The product expands Zoetis’ existing poultry vaccine portfolio, which also includes solutions targeting infectious bursal disease, infectious bronchitis, Salmonella and E. coli. The company said Poulvac Procerta HVT-ND-ILT can also be incorporated into seasonal or rotational infectious laryngotracheitis vaccination strategies.

The USDA license strengthens Zoetis’ poultry-health offering by adding a broader combination vaccine to its U.S. portfolio. While the announcement does not include financial guidance, the approval expands the company’s addressable opportunity in commercial poultry disease prevention.
Post Image
Zoetis Wins USDA License for 75-Day Cytopoint Plus Allergy Treatment for Dogs

Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Cytopoint Plus, a next-generation monoclonal antibody designed to provide 75 days of allergic itch relief in dogs with allergic dermatitis.

The treatment has the longest dosing interval among currently licensed monoclonal antibodies for canine allergic dermatitis. Cytopoint Plus is administered by a veterinarian as a single subcutaneous injection every 75 days, or about 10.7 weeks, potentially reducing the frequency of clinic visits and missed treatments.

Cytopoint Plus works by targeting and neutralizing interleukin-31, or IL-31, a protein involved in transmitting itch signals in dogs. Zoetis said the treatment begins relieving allergic itch within one day and maintains efficacy for 75 days.

The product expands Zoetis’ existing canine dermatology franchise, which already includes Cytopoint and Apoquel. Standard Cytopoint generally provides four to eight weeks of relief, while Cytopoint Plus extends the treatment interval to approximately 75 days.

In studies supporting the license, Cytopoint Plus demonstrated efficacy through Day 75 and had a safety profile similar to Cytopoint, with reduced itch scores versus controls observed through Day 90 in some dogs.

The approval strengthens Zoetis’ position in canine dermatology by adding a longer-acting option to a portfolio spanning injectable biologics and oral therapies, while addressing treatment adherence and convenience for both veterinarians and pet owners.
Zoetis Secures FDA Emergency Authorization for Simparica Trio Against New World Screwworm

Zoetis (NYSE: ZTS) has received Emergency Use Authorization from the U.S. Food and Drug Administration for Simparica Trio to treat New World screwworm infestations in dogs and puppies, expanding the animal-health company’s response to the emerging parasite threat.

New World screwworm larvae feed on the living tissue of animals, including pets, livestock and wildlife, and untreated infestations can cause severe injury, pain and death. Zoetis said the threat has recently prompted several U.S. states to introduce treatment requirements for domestic animals moving across borders from affected areas.

Simparica Trio Gains Important New Emergency Use

Simparica Trio is already a major Zoetis parasite-control product, providing monthly protection against heartworm disease, fleas, ticks, roundworms and hookworms. The FDA authorization now permits its emergency use for treatment of New World screwworm larvae in dogs and puppies.

Importantly, the authorization is an EUA rather than a full FDA approval for the new indication. The emergency authorization remains effective only while the conditions supporting the FDA's emergency declaration remain in place, unless it is revoked earlier.

Zoetis Expands Multi-Species Screwworm Response

The authorization broadens Zoetis' response beyond livestock. The company already offers Dectomax-CA1 for New World screwworm prevention and treatment in cattle, while emergency authorizations also cover certain uses of Dectomax products in dairy cattle, swine, sheep, deer and horses.

For Zoetis, the Simparica Trio authorization strengthens its position in parasite control while demonstrating the company's ability to rapidly extend existing products in response to emerging animal-health threats. Although the immediate financial contribution is uncertain, the authorization could support Simparica Trio's strategic importance within Zoetis' companion-animal portfolio if the New World screwworm threat continues to expand in the U.S.
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026.
Zoetis Inc. (NYSE: ZTS) has agreed to acquire the animal genomics business of Neogen Corporation (NASDAQ: NEOG) for $160 million, subject to customary adjustments.

The transaction strengthens Zoetis’ Precision Animal Health portfolio by integrating Neogen’s global genomics capabilities, including five laboratories across the U.S., Brazil, Australia, China and the U.K. The business provides fixed array and sequencing technologies, along with software tools that support data-driven breeding and health decisions, and is a leader in U.S. beef and dairy genomics.

Zoetis said the acquisition will enhance predictive insights and individualized care across livestock and companion animals. The deal is expected to close in the second half of 2026, pending regulatory approvals and customary conditions.
Source:Business Wire
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Company will review fourth quarter and full year 2025 financial results.
Zoetis to Participate in J.P. Morgan Healthcare Conference on January 12

Zoetis Inc. announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The company will be represented by Chief Executive Officer Kristin Peck and Chief Financial Officer Wetteny Joseph, who will respond to questions from analysts beginning at 10:30 a.m. PT.

A live audio webcast of the presentation will be available through Zoetis’ investor relations website, with a replay accessible following the conclusion of the event.

Source: Business Wire
Zoetis announced plans to issue $1.75 billion in convertible senior notes due 2029 in a private offering to qualified institutional buyers, with an option for initial purchasers to buy up to an additional $250 million in notes. The company expects to use substantially all net proceeds to fund capped call transactions and to repurchase shares of its common stock, with remaining proceeds allocated to further share buybacks to be completed by no later than the first quarter of 2026 under its existing $6 billion repurchase program.

The notes will be senior, unsecured obligations bearing semi-annual interest and maturing on June 15, 2029, unless earlier converted, redeemed, or repurchased. Upon conversion, Zoetis plans to settle the principal amount in cash and may settle any excess conversion value in cash, shares, or a combination of both. The capped call transactions are intended to reduce potential dilution from conversion and offset cash payments above the principal amount, subject to a cap. Zoetis noted that related hedging activity and concurrent share repurchases could influence the market price of its common stock and the notes.

Source: Zoetis Inc., Business Wire.
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026.
Zoetis Wins Health Canada Approval for Portela, a Long-Acting Osteoarthritis Pain Treatment for Cats

Zoetis announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to relieve osteoarthritis pain in cats for up to three months with a single injection. Portela targets nerve growth factor (NGF), a key driver of OA pain, and has shown strong effectiveness and good tolerability in a nine-month European field study, including in cats with early-stage kidney disease.

Already approved in the EU, Portela is expected to become commercially available in Canada and Europe in 2026. The treatment offers a long-acting alternative for cats that are difficult to medicate regularly, addressing a major unmet need given that OA is common but often underdiagnosed—only 18% of affected cats receive a formal OA pain diagnosis.

Portela joins Zoetis’ expanding feline pain-management portfolio alongside Solensia, leveraging a unique NGF-binding mechanism to extend duration of relief. The product is administered subcutaneously every three months and is not recommended for use in breeding, pregnant, lactating cats, or cats under 12 months of age.

Zoetis highlighted the approval as part of its broader innovation strategy within companion-animal medicine.
Video Thumbnail
05-08-26The Investor
Video Thumbnail
10-03-25WS News